Protagonist Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Protagonist Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 48.3 times. Higher than almost all Healthcare companies in United States.
- Debt Due Cover Ratio: Debt due within a year is covered 25.3 times by its yearly operating cash. Higher than 91% of Healthcare companies in United States.
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $260 of operating cash. Higher than 85% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
$260Over the last 3 years, every $100 of reported profit came with $260 of operating cash.
Higher than 85% of Healthcare companies in United States.
Self-Funding Ratio
48.3×Over the last 3 years its own operating cash covered its investment spending (capex) 48.3 times.
Higher than almost all Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
−$14Sales grew 73% in 3 years, but profit fell: $14 less profit per $100 of extra sales.
Lower than 75% of Healthcare companies in United States.
Asset Productivity Ratio
+73% / +170%In 3 years sales changed by +73% while total assets changed by +170%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
25.3×Debt due within a year is covered 25.3 times by its yearly operating cash.
Higher than 91% of Healthcare companies in United States.
Cash Cushion Ratio
+6%Cash, after subtracting all debt, equals 6% of its market value (net cash).
Lower than 55% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Protagonist Therapeutics, Inc. owes $0.05 for every $1 it owns. Protagonist Therapeutics, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
135.5Investors pay $135.5 for every $1 of Protagonist Therapeutics, Inc.'s yearly profit, higher than 93% of Healthcare companies in United States.
P/B ratio
10.73The share price is 10.73 times Protagonist Therapeutics, Inc.'s book value per share, higher than 87% of Healthcare companies in United States.
Market cap
$9.0 BThe total market value of all of Protagonist Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 89% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$842 MWhat Protagonist Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$13.01Net worth divided by the number of shares. The share price of $139.53 is 10.7 times this, which is the P/B above.
Return on equity (ROE)
11.0%Protagonist Therapeutics, Inc. earned 11.0% on its shareholders' money over the last year, higher than 84% of Healthcare companies in United States.
Owes vs Owns
0.05×Protagonist Therapeutics, Inc. owes $0.05 for every $1 it owns (low), lower than 97% of Healthcare companies in United States.
Dividend yield
NoneProtagonist Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
-89%Revenue fell 89% in the year to Dec 2025, and grew 20% a year on average over 3 years.
Profit growth
LossProtagonist Therapeutics, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Profit margin
-282.8%Protagonist Therapeutics, Inc. lost $283 for every $100 of revenue.
Cash vs debt
Net cashProtagonist Therapeutics, Inc. held $557 M more cash than debt (net cash) at Dec 2025.
Questions
What is Protagonist Therapeutics, Inc.'s P/E ratio?
Investors pay $135.5 for every $1 of Protagonist Therapeutics, Inc.'s yearly profit, higher than 93% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Protagonist Therapeutics, Inc.: $9.0 B ÷ $842 M (30 Jun 2026) = 10.7.
What is Protagonist Therapeutics, Inc.'s return on equity?
Protagonist Therapeutics, Inc. earned 11.0% on its shareholders' money over the last year, higher than 84% of Healthcare companies in United States.
How much does Protagonist Therapeutics, Inc. owe compared with what it owns?
Protagonist Therapeutics, Inc. owes $0.05 for every $1 it owns (low), lower than 97% of Healthcare companies in United States.
Does Protagonist Therapeutics, Inc. pay a dividend?
No. Protagonist Therapeutics, Inc. does not currently pay a dividend.
Is Protagonist Therapeutics, Inc.'s revenue growing?
Revenue fell 89% in the year to Dec 2025, and grew 20% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.